Barry S Coller

List of Publications by Year in Descending Order

130 papers	6,885 citations	40 h-index	82 g-index
136 ext. papers	7,475 ext. citations	7.6 avg, IF	5.9 L-index

#	Paper	IF	Citations
130	KL2 scholarsQperceptions of factors contributing to sustained translational science career success.. *Journal of Clinical and Translational Science*, **2022**, 6, e34	0.4	1
129	Platelet binding to polymerizing fibrin is avidity driven and requires activated IIb3 but not fibrin cross-linking. *Blood Advances*, **2021**, 5, 3986-4002	7.8	1
128	Electron microscopy shows that binding of monoclonal antibody PT25-2 primes integrin IIb3 for ligand binding. *Blood Advances*, **2021**, 5, 1781-1790	7.8	1
127	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. *Thrombosis and Haemostasis*, **2021**, 121, 1562-1573	7	1
126	Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel IIb3 Receptor Antagonist. *TH Open*, **2021**, 5, e449-e460	2.7	0
125	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. *Journal of Clinical and Translational Science*, **2021**, 5, e96	0.4	2
124	CTSA pharmacies: Contribution to research and public health during the COVID-19 pandemic. *Journal of Clinical and Translational Science*, **2021**, 5, e108	0.4	0
123	The Rockefeller Team Science Leadership training program: Curriculum, standardized assessment of competencies, and impact of returning assessments. *Journal of Clinical and Translational Science*, **2021**, 5, e165	0.4	
122	Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction. *EuroIntervention*, **2021**, 17, e401-e410	3.1	5
121	Cryo-Electron Microscopy Structure of the IIb3-Abciximab Complex. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 624-637	9.4	8
120	Dominant role of IIb3 in platelet interactions with cross-linked fibrin fragment D-dimer. *Blood Advances*, **2020**, 4, 2939-2949	7.8	4
119	First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin IIb3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction. *Journal of the American Heart Association*, **2020**, 9, e016552	6	7
118	Preclinical Studies of RUC-4, a Novel Platelet IIb3 Antagonist, in Non-Human Primates and With Human Platelets. *Journal of Clinical and Translational Science*, **2019**, 3, 65-74	0.4	7
117	Ethics of Human Genome Editing. *Annual Review of Medicine*, **2019**, 70, 289-305	17.4	35
116	Novel Pure V3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations. *ACS Pharmacology and Translational Science*, **2019**, 2, 387-401	5.9	10
115	New methodologies to accurately assess circulating active transforming growth factor-1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices. *Translational Research*, **2018**, 192, 15-29	11	14
114	Expand the scorecard for health-care reform to achieve a better result and enhance clinical and translational science. *Journal of Clinical and Translational Science*, **2018**, 2, 276-279	0.4	

113	Helping Basic Scientists Engage With Community Partners to Enrich and Accelerate Translational Research. *Academic Medicine*, **2017**, 92, 374-379	3.9	22
112	Toward Responsible Human Genome Editing. *JAMA - Journal of the American Medical Association*, **2017**, 317, 1829-1830	27.4	11
111	The Rockefeller University Clinical Scholars (KL2) Program 2006-2016. *Journal of Clinical and Translational Science*, **2017**, 1, 285-291	0.4	3
110	Informed consent for next-generation nucleotide sequencing studies: Aiding communication between participants and investigators. *Journal of Clinical and Translational Science*, **2017**, 1, 115-120	0.4	5
109	IIb3 binding to a fibrinogen fragment lacking the chain dodecapeptide is activation dependent and EDTA inducible. *Blood Advances*, **2017**, 1, 417-428	7.8	8
108	Increased Smad2/3 phosphorylation in circulating leukocytes and platelet-leukocyte aggregates in a mouse model of aortic valve stenosis: Evidence of systemic activation of platelet-derived TGF-1 and correlation with cardiac dysfunction. *Blood Cells, Molecules, and Diseases*, **2016**, 58, 1-5	2.1	4
107	IIb3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1898-907	11.5	33
106	A data-rich recruitment core to support translational clinical research. *Clinical and Translational Science*, **2015**, 8, 91-9	4.9	10
105	The Rockefeller University Graduate Tracking Survey System. *Clinical and Translational Science*, **2015**, 8, 326-9	4.9	3
104	The Research Hospitalist: Protocol Enabler and Protector of Participant Safety. *Clinical and Translational Science*, **2015**, 8, 174-6	4.9	3
103	Planning for the future workforce in hematology research. *Blood*, **2015**, 125, 2745-52	2.2	9
102	Blood at 70: its roots in the history of hematology and its birth. *Blood*, **2015**, 126, 2548-60	2.2	16
101	A novel class of ion displacement ligands as antagonists of the IIb3 receptor that limit conformational reorganization of the receptor. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1148-53	2.9	17
100	The platelet: life on the razor edge between hemorrhage and thrombosis. *Transfusion*, **2014**, 54, 2137-46	2.9	1
99	The Rockefeller University Navigation Program: a structured multidisciplinary protocol development and educational program to advance translational research. *Clinical and Translational Science*, **2014**, 7, 12-9	4.9	8
98	RUC-4: a novel IIb3 antagonist for prehospital therapy of myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 2321-9	9.4	47
97	Talin-driven inside-out activation mechanism of platelet IIb3 integrin probed by multimicrosecond, all-atom molecular dynamics simulations. *Proteins: Structure, Function and Bioinformatics*, **2014**, 82, 3231-3240	4.2	16
96	Association between shear stress and platelet-derived transforming growth factor-1 release and activation in animal models of aortic valve stenosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 1924-32	9.4	26

95	A Brief History of Ideas About Platelets in Health and Disease **2013**, xix-xliv		4
94	Three-dimensional reconstruction of intact human integrin IIb3: new implications for activation-dependent ligand binding. *Blood*, **2013**, 122, 4165-71	2.2	36
93	Identification of the thiol isomerase-binding peptide, mastoparan, as a novel inhibitor of shear-induced transforming growth factor 1 (TGF-1) activation. *Journal of Biological Chemistry*, **2013**, 288, 10628-39	5.4	21
92	Swing-out of the 3 hybrid domain is required for IIb3 priming and normal cytoskeletal reorganization, but not adhesion to immobilized fibrinogen. *PLoS ONE*, **2013**, 8, e81609	3.7	8
91	The Hematologist Discoverer **2013**, 10,		2
90	Platelet TGF-1 contributions to plasma TGF-1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. *Blood*, **2012**, 119, 1064-74	2.2	117
89	Structure-based virtual screening of small-molecule antagonists of platelet integrin IIb3 that do not prime the receptor to bind ligand. *Journal of Computer-Aided Molecular Design*, **2012**, 26, 1005-15	4.2	18
88	Structure-guided design of a high-affinity platelet integrin IIb3 receptor antagonist that disrupts Mg2+ binding to the MIDAS. *Science Translational Medicine*, **2012**, 4, 125ra32	17.5	67
87	Translating from the rivers of Babylon to the coronary bloodstream. *Journal of Clinical Investigation* , **2012**, 122, 4293-9	15.9	12
86	Changes in Plasma TGF-1 Levels in a Murine Model of Aortic Stenosis (Surgical Constriction of the Ascending Aorta) in C57Bl/6 (wild-type) Mice and Mice with a Targeted Deletion of Platelet TGF-1. *Blood*, **2012**, 120, 1065-1065	2.2	
85	Three-Dimensional Reconstruction of Intact Human Integrin IIb3 in a Phospholipid Bilayer Nanodisc. *Blood*, **2012**, 120, 92-92	2.2	
84	Realigning incentives to achieve health care reform. *JAMA - Journal of the American Medical Association*, **2011**, 306, 204-5	27.4	3
83	Identification of Platelet Releasate Proteins that Bind to Mastoparan, a Peptide that Inhibits Shear-Induced TGF-1 Activation,. *Blood*, **2011**, 118, 3271-3271	2.2	
82	Mice with Megakaryocyte-Specific Deletion of TGF-1 Are Partially Protected From Developing Cardiac Fibrosis and Systolic Dysfunction in a Pressure Overload Model. *Blood*, **2011**, 118, 362-362	2.2	
81	Structure-Guided Design of A Novel High Affinity Integrin IIb3 Receptor Antagonist (RUC-2) That Displaces Mg2+ From the 3 MIDAS,. *Blood*, **2011**, 118, 3255-3255	2.2	
80	Effects of limiting extension at the alphaIIb genu on ligand binding to integrin alphaIIbbeta3. *Journal of Biological Chemistry*, **2010**, 285, 17604-13	5.4	20
79	Closed headpiece of integrin IIb3 and its complex with an IIb3-specific antagonist that does not induce opening. *Blood*, **2010**, 116, 5050-9	2.2	85
78	Traversing the valley of death: a guide to assessing prospects for translational success. *Science Translational Medicine*, **2009**, 1, 10cm9	17.5	63

77	The Society for Clinical and Translational Science (SCTS) is Born **2009**, 2, 254-255		78
76	Targeted molecular dynamics reveals overall common conformational changes upon hybrid domain swing-out in beta3 integrins. *Proteins: Structure, Function and Bioinformatics*, **2009**, 77, 477-89	4.2	17
75	Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. *Blood*, **2009**, 114, 195-201	2.2	29
74	Structural, Functional, and Dynamic Characterization of the Binding Site of RUC-1, a Novel IIb-Specific Inhibitor of Integrin IIbIII.. *Blood*, **2009**, 114, 151-151	2.2	1
73	Macrophage Depletion Leads to Modification of Thalassemic Phenotype.. *Blood*, **2009**, 114, 2023-2023	2.2	1
72	In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring- and shear-dependent activation of platelet-derived TGF-beta1. *PLoS ONE*, **2009**, 4, e6608	3.7	37
71	Platelets Are the Major Source of Circulating TGF-1 in Mice.. *Blood*, **2009**, 114, 4021-4021	2.2	
70	Thinking globally, acting locally: Rockefeller University enterprising CTSA work. *Clinical and Translational Science*, **2008**, 1, 190-1	4.9	3
69	Morphological and functional platelet abnormalities in Berkeley sickle cell mice. *Blood Cells, Molecules, and Diseases*, **2008**, 41, 109-18	2.1	13
68	Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. *Blood*, **2008**, 111, 1248-56	2.2	56
67	In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1. *Blood*, **2008**, 112, 3650-60	2.2	106
66	The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. *Blood*, **2008**, 112, 3011-25	2.2	270
65	Functional and computational studies of the ligand-associated metal binding site of beta3 integrins. *Proteins: Structure, Function and Bioinformatics*, **2008**, 71, 1779-91	4.2	20
64	Translational research: forging a new cultural identity. *Mount Sinai Journal of Medicine*, **2008**, 75, 478-87		26
63	Limiting IIb Extension at the Genu Differentially Affects Binding of Small and Large Ligands to IIbIII. *Blood*, **2008**, 112, 255-255	2.2	
62	Thrombospondin 1 (TSP-1) Partially Contributes to Shear or Stirring- Dependent TGF-beta1 Activation In Vitro and During Platelet-Rich Thrombi Formation In Vivo.. *Blood*, **2008**, 112, 1847-1847	2.2	
61	Structural and Therapeutic Insights from the Species Specificity and in Vivo Antithrombotic Activity of a Novel IIb-Specific IIbIII Antagonist. *Blood*, **2008**, 112, 256-256	2.2	1
60	Disulfide bond disruption by a III-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active IIbIII. *Thrombosis and Haemostasis*, **2007**, 98, 1257-1265	7	36

59	Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation. *Blood*, **2007**, 109, 3725-32	2.2	26
58	Generation of Megakaryocytes from Human Embryonic Stem Cells.. *Blood*, **2007**, 110, 1265-1265	2.2	
57	Activation of Transforming Growth Factor □1 (TGF-□1) Released by Platelets Is Enhanced by Shear and Occurs in Platelet-Rich Thrombi In Vivo.. *Blood*, **2007**, 110, 3632-3632	2.2	
56	Disulfide bond disruption by a beta 3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active alpha IIb beta 3. *Thrombosis and Haemostasis*, **2007**, 98, 1257-65	7	19
55	Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3). *Human Mutation*, **2006**, 27, 359-69	4.7	41
54	Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. *Blood*, **2006**, 107, 1651-8	2.2	98
53	The physician-scientist, the state, and the oath: thoughts for our times. *Journal of Clinical Investigation*, **2006**, 116, 2567-70	15.9	6
52	Equilibrium and Non-Equilibrium Molecular Dynamics Simulations Provide Potential Mechanisms for the Loss of Ligand Binding to ⨊b□3 Mutants Affecting the Ligand-Induced Metal Binding Site (LIMBS).. *Blood*, **2006**, 108, 1805-1805	2.2	
51	Application of High Throughput Screening To Identify Novel Small Molecule Inhibitors of ⨊b□3-Mediated Platelet Adhesion to Fibrinogen.. *Blood*, **2006**, 108, 144-144	2.2	
50	Functional and Computational Analysis of the Role of the Adjacent to Metal Ion-Dependent Adhesion Site (ADMIDAS) of Integrin ⨊b□3.. *Blood*, **2006**, 108, 143-143	2.2	
49	Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 658-70	9.4	229
48	Neither Free ⨊b nor Free □3 Limits ⨊b□3 Biogenesis, and Pro-⨊b□3 Adopts a Conformation Akin to Ligand-Bound Mature ⨊b□3.. *Blood*, **2005**, 106, 1656-1656	2.2	
47	Mechanistic insights from a refined three-dimensional model of integrin alphaIIbbeta3. *Journal of Biological Chemistry*, **2004**, 279, 24624-30	5.4	9
46	Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13114-20	11.5	74
45	Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. *Nature*, **2004**, 432, 59-67	50.4	679
44	Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. *Journal of the American College of Cardiology*, **2004**, 44, 1570-7	15.1	40
43	Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, **2004**, 126, 234S-264S	5.3	494
42	Three Separate Glanzmann Thrombasthenia Mutants Affecting the ⨊b □-Propeller Result in Production of Normally Stable Pro-⨊b, but Impaired Progression from Endoplasmic Reticulum to Golgi.. *Blood*, **2004**, 104, 741-741	2.2	4

41	Evidence Supporting Thiol-Disulfide Exchange as a Novel Mechanism of Platelet TGF-β1 Activation.. *Blood*, **2004**, 104, 2621-2621	2.2	
40	Crystal Structure of the Integrin αIIbβ3 Headpiece at 2.7–3.1 A : Structure, Mechanisms of Activation and Ligand Binding, Inhibition by Eptifibatide, Tirofiban, and mAb 10E5, and Structure of the HPA-1 Alloantigen Epitope.. *Blood*, **2004**, 104, 327-327	2.2	
39	Differences in αIIbβ3 Biogenesis Dynamics between Umbilical Cord Blood-Derived Human Megakaryocyte-Like Cells and Transfected HEK293 Cells as Revealed by a Mathematical Model.. *Blood*, **2004**, 104, 1559-1559	2.2	1
38	Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 3047-51	11.5	365
37	Professing and living the oath: teaching medicine as a profession. *American Journal of Medicine*, **2002**, 112, 744-8	2.4	8
36	Science and humanism: the twin pillars of medicine. *Mount Sinai Journal of Medicine*, **2002**, 69, 277-9		
35	Platelet adhesion to fibrinogen coated at various densities. *Annals of the New York Academy of Sciences*, **2001**, 936, 464-5	6.5	1
34	Variable protection of beta 3-integrin--deficient mice from thrombosis initiated by different mechanisms. *Blood*, **2001**, 98, 1055-62	2.2	100
33	Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. *Circulation*, **2001**, 103, 2501-7	16.7	124
32	A Hamster Antibody to the Mouse Fibrinogen Chain Inhibits Platelet-fibrinogen Interactions and FXIIIa-mediated Fibrin Cross-linking, and Facilitates Thrombolysis. *Thrombosis and Haemostasis*, **2001**, 86, 1047-1056	7	19
31	A naturally occurring mutation near the amino terminus of αIIb defines a new region involved in ligand binding to αIIbβ3. *Blood*, **2000**, 95, 180-188	2.2	56
30	Hemostasis in the Mouse (Mus musculus): A Review. *Thrombosis and Haemostasis*, **1999**, 81, 177-188	7	110
29	Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. *Circulation*, **1999**, 100, 1977-82	16.7	97
28	Rapid platelet-function assay: an automated and quantitative cartridge-based method. *Circulation*, **1999**, 99, 620-5	16.7	244
27	Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. *Biochemical and Biophysical Research Communications*, **1999**, 262, 167-73	3.4	39
26	Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. *Journal of Clinical Investigation*, **1999**, 103, 229-38	15.9	581
25	Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). *Circulation*, **1998**, 98, 742-8	16.7	67
24	Glycoprotein IIb Leu214Pro Mutation Produces Glanzmann Thrombasthenia With Both Quantitative and Qualitative Abnormalities in GPIIb/IIIa. *Blood*, **1998**, 91, 1562-1571	2.2	49

23	Hematologically important mutations: Glanzmann thrombasthenia. *Blood Cells, Molecules, and Diseases*, **1997**, 23, 39-51	2.1	70
22	GPIIb/IIIa Antagonists: Pathophysiologic and Therapeutic Insights from Studies of c7E3 Fab. *Thrombosis and Haemostasis*, **1997**, 78, 730-735	7	125
21	In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. *Circulation*, **1997**, 95, 614-7	16.7	71
20	Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. *Circulation*, **1997**, 95, 860-7	16.7	77
19	The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. *Molecular Immunology*, **1995**, 32, 1271-81	4.3	94
18	Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. *Circulation*, **1995**, 92, 2373-80	16.7	190
17	New Antiplatelet Agents: Platelet GPIIb/llla Antagonists. *Thrombosis and Haemostasis*, **1995**, 74, 302-308	7	95
16	Partial Inhibition of Platelet Aggregation and Fibrinogen Binding by a Murine Monoclonal Antibody to GPIIIa: Requirement for Antibody Bivalency. *Thrombosis and Haemostasis*, **1994**, 72, 964-972	7	16
15	Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. *Annals of the New York Academy of Sciences*, **1991**, 614, 193-213	6.5	121
14	Platelets and thrombolytic therapy. *New England Journal of Medicine*, **1990**, 322, 33-42	59.2	440
13	Immunoblot analysis of platelet glycoprotein IIb in patients with Glanzmann thrombasthenia in Israel. *British Journal of Haematology*, **1989**, 72, 415-23	4.5	17
12	Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. *New England Journal of Medicine*, **1987**, 317, 1037-42	59.2	64
11	Blood elements at surfaces: platelets. *Annals of the New York Academy of Sciences*, **1987**, 516, 362-79	6.5	9
10	Diagnostic and therapeutic applications of antiplatelet monoclonal antibodies. *Biorheology*, **1987**, 24, 649-58	1.7	5
9	Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. *British Journal of Haematology*, **1986**, 62, 723-35	4.5	59
8	Report of the Working Party on Hybridoma-Derived Monoclonal Antibodies to Platelets. *Thrombosis and Haemostasis*, **1984**, 51, 169-173	7	14
7	Dibucaine-Activated Platelet Protease(S) Digests GPIb-EDTA Only Partially Inhibits **1981**, 46, 0333		
6	Von Willebrand disease: combined qualitative and quantitative abnormalities. *New England Journal of Medicine*, **1977**, 296, 1024-30	59.2	44

5	Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. *American Journal of Hematology*, **1977**, 3, 105-19	7.1	101
4	Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. *Journal of Clinical Investigation*, **1977**, 60, 302-12	15.9	58
3	Studies of the human factor VIII/von Willebrand factor protein I. Comparison of the protein found in normal, von Willebrand disease and hemophilia A. *Thrombosis Research*, **1975**, 6, 93-108	8.2	14
2	Studies on the Factor VIII/von Willebrand factor antigen on human platelets. *Thrombosis Research*, **1975**, 6, 469-80	8.2	40
1	Reversible decrease in platelet retention by glass bead columns (adhesiveness) induced by disturbing the blood. *Experimental Biology and Medicine*, **1971**, 136, 769-71	3.7	30